Venus Remedies has secured marketing authorizations for three variants of Docetaxel in Israel and Cytarabine 100MG in Colombia. The approved Docetaxel variants (160MG/8ML, 80MG/4ML, 20MG/1ML) and Cytarabine further solidify its commitment to advancing healthcare solutions globally.
Earlier, the company had unveiled a significant transformation of its consumer healthcare division, R3SET. This strategic pivot marks R3SET's foray into the wellness arena, coupled with the expansion of its pain management portfolio, showcasing the company's holistic approach to wellness solutions.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1520.00 |
Dr. Reddys Lab | 6260.00 |
Cipla | 1419.55 |
Zydus Lifesciences | 988.00 |
Lupin | 1647.75 |
View more.. |